4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Citius Oncology, Inc. (CTOR) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Cranford, United States. Its market capitalization is roughly $64 million. In the fiscal year ended 2025-09-30, CTOR reported $0M in revenue and ($25M) in net income.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
Interactive charts & full statements → Open the CTOR valuation workbench →
| Income statement | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($24M) | ($21M) | ($12M) | ($5M) |
| Net Income | ($25M) | ($21M) | ($13M) | ($5M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $2M | $4M | $0M | $0M | $0M | — |
| Gross Profit | $1M | $3M | — | — | $0M | $0M |
| Operating Income (EBIT) | ($29M) | ($5M) | ($5M) | ($5M) | ($8M) | — |
| Net Income | ($27M) | ($6M) | ($5M) | ($5M) | ($8M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Total Assets | $101M | $84M | $48M | $43M |
| Total Liabilities | $56M | $38M | $22M | $6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CTOR viewer.
About TickerBase · Data methodology & sources